Navigation Links
Multiple Sclerosis Patients to Benefit With AVONEX(R) Nurse Services Program

Biogen Idec announced the national launch of the new AVONEX(R) (Interferon beta-1a) Nurse Services program which is designed to help people //with multiple sclerosis (MS) as they begin and continue treatment with AVONEX, the most prescribed treatment for relapsing forms of MS worldwide.

"As a person living with MS and as a nurse I can attest first-hand that nurses play an important role in working closely with patients and their healthcare providers in both the treatment and care of MS," said Marie Stallbaum, RN, BSN, a nurse with the AVONEX Nurse Services Program. "Nurses in this program will be dedicated to helping MS patients live the fullest and most active lives possible."

The AVONEX Nurse Services program will have registered nurses covering the majority of the country who will provide a wide range of services that will help patients in a home setting. Services include:

?At-home injection training and follow-up visit(s)
?Assistance in managing injection anxiety)
?Management of disease expectations
?Tips for managing common side effects
?Valuable phone counseling
"The AVONEX Nurse Services program is the latest example of our efforts to provide the best care and support for patients," said Michael Panzara, MD, MPH, Vice President and Chief Medical Officer, Neurology Strategic Business Unit, Biogen Idec. "From our research efforts aimed at discovering new treatment options to the unparalleled support services we offer patients, Biogen Idec is committed to advancing the care of people living with MS."

AVONEX has been proven to slow the progression of physical disability, reduce the frequency of relapses, and is effective for patients who have their first clinical MS attack and have a brain MRI scan that suggests MS. AVONEX is also the only once-a-week therapy for MS.

The clinical benefits of AVONEX have been supported by a number of recent enhancements to the product's delivery. AVONEX can now be administered with a smaller needle, which can further advance patient comfort. The storage and transportation of AVONEX has been made even easier with the introduction of ambient storage for the AVONEX luer-lock prefilled syringe. A new AVOGRIP(TM) is available to aid patients in the administration of injections. These improvements are part of the company's efforts to improve patients' experience with AVONEX. In addition, AVONEX patients have shown significantly higher adherence rates than the other approved disease-modifying therapies (DMTs).(1)

AVONEX is the most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is marketed internationally in more than 90 countries.

AVONEX was the first treatment approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS; this use was approved in Europe in 2002 and in the U.S. in 2003. The most common side effects associated with AVONEX multiple sclerosis treatment are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.

AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. AVONEX should not be used by pregnant women. Patients with cardiac disease should be closely monitored. Patients should also be monitored for signs of hepatic injury. Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX. Rare cases of anaphylaxis have been reported

Source-IANS/N
'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... Plains, NJ (PRWEB) , ... January 19, 2017 ... ... board certified dermatologist by the American Board of Dermatology and fellowship trained Mohs ... of the National Institutes of Health, Dr. Li completed his internship in internal ...
(Date:1/19/2017)... Angeles, California (PRWEB) , ... January 19, 2017 ... ... the hands of a doctor who administered fillers that resulted in severe facial ... unprecedented case was taken on by doctors at UCLA Medical Center, who removed ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... financial planning assistance to commercial and residential clients in the California Bay Area, is ... positive heart health in the region. , Heart disease is the primary killer of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology: